Two-drug therapy reduces heart artery plaque more than statins alone


A cardiologist reads a patient's medical documents in a hospital roomShare on Pinterest
Extra intensive ldl cholesterol therapy might reverse artery plaque, a brand new trial finds. Halfpoint Pictures/ Second/Getty Pictures
  • A brand new examine suggests {that a} mixture remedy of rosuvastatin plus ezetimibe resulted in a higher discount in coronary plaque quantity than atorvastatin alone.
  • Mixture remedy additionally lowered LDL ldl cholesterol greater than atorvastatin alone.
  • There was additionally a bigger lower in complete coronary plaque quantity and noncalcified plaque when utilizing mixture remedy.
  • Though the findings counsel that aggressive ldl cholesterol reducing can shrink and stabilize current plaque, additional analysis is important to find out whether or not these modifications scale back the danger of coronary heart assaults, strokes, and different cardiovascular occasions.

Though atherosclerosis is commonly thought of a progressive situation, reducing LDL ldl cholesterol may help scale back current plaque buildup and the danger of atherosclerotic heart problems.

Now, a brand new examine means that an intensive cholesterol-lowering therapy combining two drugs might shrink plaque buildup within the coronary heart’s arteries extra successfully than excessive dose statin remedy alone, which might assist reverse a few of the artery harm related to atherosclerosis.

The examine, revealed in JAMA Cardiology, discovered that 90% of contributors receiving mixture remedy skilled a discount in coronary plaque quantity, in contrast with 75% of these taking a excessive dose statin alone.

Moreover, mixture remedy additionally produced higher reductions in complete plaque quantity and noncalcified plaque, a kind of fatty deposit that could be extra susceptible to rupture.

Nonetheless, additional analysis is important to find out whether or not these enhancements in artery plaque translate into fewer coronary heart assaults, strokes, and different cardiovascular occasions.

The randomized scientific trial included 104 adults in Denmark who had secure chest ache and important CAD. Individuals had coronary artery narrowing of greater than 50%, confirmed by means of coronary computed tomography angiography (CTA), and none had beforehand taken statins.

Researchers randomly assigned contributors to one in every of two therapy teams for 18 months. This included the usual intensive statin therapy group, which obtained atorvastatin 40 milligrams (mg) day by day, or those that obtained a extra intensive mixture therapy of rosuvastatin 40 mg day by day alongside ezetimibe 10 mg day by day.

Atorvastatin and rosuvastatin are statins, which scale back the quantity of ldl cholesterol produced by the liver. Ezetimibe works in a different way by decreasing ldl cholesterol absorption within the gut. Combining the 2 drugs can subsequently decrease LDL ldl cholesterol by means of complementary mechanisms.

Individuals underwent coronary CTA earlier than therapy, after 9 months, and on the finish of the 18-month examine interval to evaluate modifications in plaque quantity.

The researchers discovered that contributors receiving rosuvastatin and ezetimibe skilled considerably higher reductions in LDL ldl cholesterol than these taking atorvastatin alone.

LDL levels of cholesterol decreased by 65% within the mixture remedy group, falling from a mean of 127.4 milligrams per deciliter (mg/dL) to 42.5 mg/dL. By comparability, contributors receiving atorvastatin alone skilled a 38% discount in LDL ldl cholesterol.

These variations had been additionally accompanied by higher reductions in coronary plaque quantity, with reductions of 21.1% amongst these receiving mixture remedy and 13.6% amongst these receiving atorvastatin alone.

“The primary rationalization is probably going the higher LDL-C discount, quite than a particular impact of the medication themselves,” lead examine creator Martin Bødtker Mortensen, MD, PhD, Scientific Affiliate Professor within the Division of Scientific Drugs Cardiology at Aarhus College, defined to Medical Information Immediately.

“The mixture achieved a mean LDL-C of roughly 1.1 mmol/L in contrast with 1.8 mmol/L with atorvastatin alone. This translated into considerably higher plaque regression,” he stated.

“Atherosclerosis isn’t essentially an irreversible illness. Our findings exhibit that substantial regression is feasible, significantly when intensive therapy is initiated in beforehand statin-naive sufferers. Importantly, decrease achieved LDL-C ranges had been constantly related to higher regression,” Mortensen additional defined.

“A very powerful discovering is that coronary atherosclerosis can regress considerably with intensive LDL-C reducing. We noticed a 21% discount in complete plaque quantity and a 28% discount in noncalcified plaque quantity after 18 months of extra intensive therapy. Remarkably, 90% of sufferers skilled regression of complete plaque quantity.”
— Martin Bødtker Mortensen, MD

The variations had been additionally obvious when researchers examined noncalcified plaque. Some types of this plaque are more vulnerable to rupture, which may set off blood clot formation and doubtlessly trigger a coronary heart assault.

Noncalcified plaque quantity decreased by 28.2% within the mixture remedy group, in contrast with 20% within the atorvastatin group. Moreover, 51 out of 52 contributors receiving mixture remedy skilled a discount in noncalcified plaque quantity, in contrast with 39 contributors in the usual therapy group.

“Noncalcified plaques are usually extra biologically energetic and thought of the ‘high-risk’ part of plaques,” Mortensen famous. “The substantial discount in noncalcified plaque means that intensive LDL-C reducing considerably modifies the extra harmful a part of the underlying illness course of, quite than merely slowing plaque development.”

Apparently, researchers noticed a modest enhance in calcified plaque quantity in each therapy teams. Nonetheless, this doesn’t essentially point out that atherosclerosis was worsening.

As cholesterol-rich plaque turns into extra secure, its composition can change. Lipid-rich materials might lower whereas calcium deposits grow to be extra distinguished. This course of is related to plaque stabilization, which can scale back the probability of plaque rupture.

Consequently, modifications in plaque composition could also be simply as vital as modifications in general plaque quantity when assessing the results of cholesterol-lowering therapy. The findings counsel that intensive LDL ldl cholesterol discount might not solely scale back plaque quantity in coronary arteries but in addition alter its composition.

The FLOWPROMOTE scientific trial findings add to the rising proof that extra aggressive LDL ldl cholesterol reducing can produce significant modifications in coronary artery plaque.

Importantly, they counsel that current plaque buildup isn’t essentially irreversible. With sufficiently intensive cholesterol-lowering therapy, some deposits might shrink, doubtlessly bettering arterial situation.

Nonetheless, the outcomes ought to be interpreted with some warning. The trial included solely 104 contributors, all of whom had established CAD and had not beforehand taken statins. Due to this fact, the findings might not apply equally to folks with totally different cardiovascular danger profiles or these already receiving cholesterol-lowering therapy.

Moreover, the examine measured modifications in plaque utilizing coronary imaging quite than instantly counting cardiovascular occasions. Though plaque regression and stabilization are encouraging findings, it stays unclear whether or not the higher reductions noticed with mixture remedy will result in higher long-term scientific outcomes.

The findings additionally don’t imply that everybody with excessive ldl cholesterol ought to take two cholesterol-lowering drugs, as therapy selections will rely upon an individual’s cardiovascular danger, LDL levels of cholesterol, medical historical past, and response to current therapy.

Nonetheless, the trial gives additional proof that extra intensive ldl cholesterol administration might assist reverse a few of the plaque buildup related to CAD. Bigger, longer-term research will likely be wanted to find out whether or not these enhancements translate into significant reductions in cardiovascular occasions.

“Our findings reinforce the significance of attaining low LDL-C ranges in sufferers with established coronary illness. In addition they counsel that early initiation of intensive therapy could also be significantly vital, earlier than plaques grow to be extensively calcified. Nonetheless, additional research are wanted to ascertain how these imaging modifications translate into scientific outcomes.”
— Martin Bødtker Mortensen, MD

Mortensen stated a serious energy of the FLOWPROMOTE examine was using strict, constant guidelines for CT scans each time a affected person was examined. This ensured the pictures had been top quality and dependable sufficient to precisely monitor how artery plaque modified over time.

He added that further research from this challenge are underway to indicate which sorts of plaque can shrink, how rapidly that occurs, and the way plaque composition impacts therapy effectiveness.



Source link